Loading publications…
The last 5 uploaded publications
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Robin Kate Kelley, Anthony B. El-Khoueiry, Helen L. Reeves, Xin Wei Wang, Gregory J. Gores, Augusto Villanueva (2022). Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 3(4), pp. 386-401, DOI: 10.1038/s43018-022-00357-2.
Article145 days agoTransarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Guohong Han, Hailan Lin, Jinfang Zheng, Sadahisa Ogasawara, Ji Hoon Kim, Haitao Zhao, Chuan Li, David C. Madoff, R. Mark Ghobrial, Tomokazu Kawaoka, René Gérolami, Masafumi Ikeda, Hiromitsu Kumada, Anthony B. El-Khoueiry, Arndt Vogel, Xiang Peng, Kalgi Mody, Corina E. Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Josep M. Llovet (2025). Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. The Lancet, 405(10474), pp. 203-215, DOI: 10.1016/s0140-6736(24)02575-3.
Article145 days agoCabozantinib: An evolving therapy for hepatocellular carcinoma
Anthony B. El-Khoueiry, Diana L. Hanna, Josep M. Llovet, Robin Kate Kelley (2021). Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treatment Reviews, 98, pp. 102221-102221, DOI: 10.1016/j.ctrv.2021.102221.
Article145 days agoP-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
Sadahisa Ogasawara, Josep M. Llovet, Anthony B. El-Khoueiry, Arndt Vogel, David C. Madoff, Richard S. Finn, Zheng Ren, Kush Modi, J. Li, A.B. Siegel, Leonid Dubrovsky, Masatoshi Kudo (2020). P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment. Annals of Oncology, 31, pp. S124-S125, DOI: 10.1016/j.annonc.2020.04.189.
Article145 days agoLEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)
Anthony B. El-Khoueiry, Josep M. Llovet, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zhenggang Ren, Kalgi Mody, Jerry J Li, Abby B. Siegel, Leonid Dubrovsky, Masatoshi Kudo (2022). LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 40(4_suppl), pp. TPS494-TPS494, DOI: 10.1200/jco.2022.40.4_suppl.tps494.
Article145 days ago